Gmp Cell Therapy Consumables Market Scope And Analysis

Buy Now

GMP Cell Therapy Consumables Market - Scope by 2031

Buy Now

Report Attribute	Details
Market size in 2021	US$ 11.03 Billion
Market Size by 2028	US$ 59.99 Billion
Global CAGR (2021 - 2028)	27.5%
Historical Data	2019-2020
Forecast period	2022-2028
Segments Covered	By Product Kits Reagents/Molecular Biology Reagents Growth Factors/Cytokines and Interleukins By Cell Therapy NK Cell Therapy Stem Cell Therapy T-Cell Therapy By Process Cell Collection and Characterization/Sorting and Separation Cell Culture and Expansion/Preparation Cryopreservation Cell Processing and Formulation Cell Isolation and Activation Cell Distribution/Handling Process Monitoring and Control/Readministration/Quality Assurance By End Use Clinical Commercial Research
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Sartorius AG Thermo Fisher Scientific Inc Miltenyi Biotec BV Co KG Bio Techne Corp Corning Inc FUJIFILM Irvine Scientific Inc Lonza Group AG BPS Bioscience Inc Merck KGaA

In January 2021, Sartorius signed a strategic collaboration with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC). The collaboration advanced the scale-up of hMSC manufacturing for regenerative medicine. RoosterBio and Sartorius created a set of GMP-compatible, customer-centric protocols using RoosterBio’s hMSC and media systems alongside Sartorius’s single-use manufacturing technologies, process control software, and cell analysis tools of hMSC final product manufacturing.
In September 2020, Bio-Techne Corporation opened an ~61,000 square foot state-of-the-art Good Manufacturing Practices (GMP) manufacturing facility. Located in St. Paul, MN, the new facility is dedicated to support large-scale production of GMP-grade materials, which are an essential component for many immuno-oncology and regenerative medicine cell and gene-modified therapy workflows. This facility helps the company meet current and future demand for the GMP-grade reagents that are necessary to support the rapidly growing cell therapy market.